


Troxipide

Cat. No.:	HY-B0758		
CAS No.:	30751-05-4		
Molecular Formula:	C ₁₅ H ₂₂ N ₂ O ₄		
Molecular Weight:	294.35		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 9.09 mg/mL (30.88 mM; Need ultrasonic)
 H₂O : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.3973 mL	16.9866 mL	33.9732 mL
	5 mM	0.6795 mL	3.3973 mL	6.7946 mL
	10 mM	0.3397 mL	1.6987 mL	3.3973 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 0.91 mg/mL (3.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties^{[1][2]}.

In Vitro

Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU)^[1].
Troxipide (40 mg/kg; iv) has a $T_{1/2}$ of 210 min and 428.73 min for NCG and GUG rat, respectively^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day) ^[1]
---------------	---

Dosage:	10, 20, 40, 60 mg/kg
---------	----------------------

Administration:	Oral; daily; 2 weeks
-----------------	----------------------

Result:	The levels of these cytokines (IL-17, IL-6, TNF- α , IFN- γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.
---------	--

Animal Model:	NCG and GUG rat ^[1]
---------------	--------------------------------

Dosage:	40 mg/kg for iv
---------	-----------------

Administration:	IV
-----------------	----

Result:	Had a $T_{1/2}$ of 210 min and 428.73 min for NCG and GUG rat, respectively.
---------	--

REFERENCES

- [1]. Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10(1):13619.
- [2]. K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA